X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (666) 666
Book Chapter (5) 5
Publication (2) 2
Book / eBook (1) 1
Book Review (1) 1
Conference Proceeding (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
life sciences & biomedicine (372) 372
science & technology (372) 372
cardiovascular system & cardiology (333) 333
cardiac & cardiovascular systems (332) 332
atrial fibrillation (310) 310
humans (290) 290
male (216) 216
female (211) 211
aged (187) 187
abridged index medicus (155) 155
risk factors (139) 139
stroke (128) 128
cardiovascular (127) 127
treatment outcome (124) 124
middle aged (121) 121
cardiac arrhythmia (120) 120
heart failure (107) 107
anticoagulants (104) 104
aged, 80 and over (91) 91
atrial fibrillation - drug therapy (90) 90
mortality (88) 88
atrial fibrillation - complications (84) 84
care and treatment (84) 84
stroke - prevention & control (81) 81
registries (62) 62
patients (61) 61
internal medicine (57) 57
follow-up studies (55) 55
anticoagulants - therapeutic use (54) 54
stroke - etiology (53) 53
warfarin (53) 53
drug therapy (52) 52
time factors (51) 51
cardiology (50) 50
atrial fibrillation - diagnosis (49) 49
cardiology and cardiovascular medicine (49) 49
retrospective studies (49) 49
analysis (47) 47
anticoagulants - administration & dosage (47) 47
atrial fibrillation - epidemiology (47) 47
catheter ablation (47) 47
fibrillation (47) 47
clinical trials (46) 46
heart (46) 46
patient outcomes (46) 46
rivaroxaban (45) 45
prospective studies (44) 44
heart attacks (42) 42
ablation (41) 41
atrial fibrillation - therapy (40) 40
electrocardiography (40) 40
united states - epidemiology (40) 40
prevention (39) 39
administration, oral (38) 38
anticoagulants - adverse effects (38) 38
hemorrhage - chemically induced (38) 38
hospitalization (38) 38
peripheral vascular disease (38) 38
cardiac patients (37) 37
risk assessment (36) 36
comorbidity (35) 35
incidence (34) 34
warfarin - administration & dosage (34) 34
atrial fibrillation - physiopathology (33) 33
cardiovascular disease (33) 33
double-blind method (33) 33
proportional hazards models (32) 32
atrial fibrillation - mortality (31) 31
bleeding (31) 31
medical research (31) 31
prognosis (30) 30
anti-arrhythmia agents - therapeutic use (29) 29
hypertension (29) 29
warfarin - therapeutic use (29) 29
arrhythmia (28) 28
diabetes (28) 28
hemorrhage (28) 28
medicine, general & internal (28) 28
anticoagulation (27) 27
comparative analysis (27) 27
dosage and administration (27) 27
general & internal medicine (27) 27
medicine, experimental (27) 27
original research (27) 27
quality of life (27) 27
usage (27) 27
atrial fibrillation - surgery (26) 26
studies (26) 26
united states (26) 26
embolism - prevention & control (25) 25
medical colleges (25) 25
outcomes (25) 25
stroke - epidemiology (25) 25
warfarin - adverse effects (25) 25
confidence intervals (24) 24
defibrillators, implantable (24) 24
heart diseases (24) 24
implants, artificial (24) 24
prosthesis (24) 24
research (24) 24
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 05/2013, Volume 61, Issue 19, pp. 1998 - 2006
Journal Article
The New England journal of medicine, ISSN 1533-4406, 09/2011, Volume 365, Issue 10, pp. 883 - 891
In this trial, 14,264 patients with atrial fibrillation were randomly assigned to receive either rivaroxaban or warfarin. In a per-protocol, as-treated... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thiophenes - therapeutic use | Thiophenes - adverse effects | Humans | Middle Aged | Warfarin - adverse effects | Male | Thiophenes - administration & dosage | Warfarin - administration & dosage | Warfarin - therapeutic use | Rivaroxaban | Aged, 80 and over | Female | Stroke - epidemiology | Embolism - epidemiology | Morpholines - adverse effects | Morpholines - therapeutic use | Stroke - prevention & control | Embolism - prevention & control | Double-Blind Method | Administration, Oral | Atrial Fibrillation - drug therapy | Morpholines - administration & dosage | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Intention to Treat Analysis | Aged | Hemorrhage - chemically induced | Stroke (Disease) | Warfarin | Atrial fibrillation | Patient outcomes | Dosage and administration | Drug therapy | Comparative analysis | Risk factors | Fees & charges | Cardiac arrhythmia | Stroke | Heart attacks | Research & development--R&D | Embolisms | Equity | Equity stake | Hemorrhage | Bleeding | Embolism | Studies | Prevention | Fibrillation | Motivation | Ischemia | Thromboembolism | Drug dosages | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Anticoagulants | Morpholines | Life Sciences | Thiophenes | Atrial Fibrillation
Journal Article
The Lancet (British edition), ISSN 0140-6736, 06/2015, Volume 385, Issue 9985, pp. 2363 - 2370
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2016, Volume 67, Issue 24, pp. 2888 - 2899
Abstract Nonvitamin K-dependent oral anticoagulant agents (NOACs) are currently recommended for patients with atrial fibrillation at risk for stroke. As a... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | apixaban | stroke | edoxaban | renal dialysis | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Pyrazoles - therapeutic use | Dabigatran - pharmacokinetics | Humans | Pyridines - pharmacokinetics | Renal Insufficiency, Chronic - complications | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Thiazoles - pharmacokinetics | Warfarin - therapeutic use | Renal Insufficiency, Chronic - therapy | Kidney - metabolism | Pyrazoles - pharmacokinetics | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Stroke - prevention & control | Glomerular Filtration Rate | Pyridones - pharmacokinetics | Atrial Fibrillation - drug therapy | Anticoagulants - therapeutic use | Creatinine - urine | Warfarin - pharmacokinetics | Kidney Failure, Chronic - therapy | Rivaroxaban - pharmacokinetics | Kidney Failure, Chronic - complications | Anticoagulants - pharmacokinetics | Pyridones - therapeutic use | Hemorrhage - chemically induced | Renal Dialysis | Stroke (Disease) | Medical colleges | Care and treatment | Continuing medical education | Warfarin | Chronic kidney failure | Atrial fibrillation | Mortality | Medical care | Quality management | Urine | Confidence intervals | Disease prevention | Anticoagulants | Stroke | Hemodialysis | Kidney diseases | Metabolism | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article